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Prevalence and risk factors of the metabolic 
syndrome in young adults with childhood-onset 
hypopituitary growth hormone deficiency
Purpose: This study evaluated the prevalence of the metabolic 
syndrome (MetS) and risk factors for metabolic derangement in young 
adults with childhood-onset hypopituitary growth hormone deficiency 
(ACOHGHD). 
Methods: Thirty patients with ACOHGHD who were treated with 
hormone-replacement therapy, aged 18 to 29 years, who visited the 
Seoul National University Children’s Hospital between September 
2009 and February 2010 were enrolled. Height, weight, waist 
circumference, hip circumference, and blood pressure were measured, 
and the clinical and hormonal features were reviewed retrospectively. 
We evaluated measures of metabolic derangement in the enrolled 
patients and in the data of healthy adults aged 20 to 29 years taken 
from the 2005 Korean National Health and Nutrition Examination 
Survey (KNHANES) as part of the National Cholesterol Education 
Program-the Adult Treatment Panel III. 
Results: Compared with the KNHANES participants, patients with 
ACOHGHD had significantly large waist circumference (men and 
women), high systolic blood pressure (BP) (women) and diastolic BP 
(men), and high serum triglyceride levels (women). The duration of 
illness correlated significantly with central obesity (r
2=0.546, P=0.003). 
The prevalence of MetS was 10% in patients with ACOHGHD and 
2.3% in KNHANES participants. The prevalence of central obesity 
and MetS was higher in patients with ACOHGHD than in KNHANES 
participants (P<0.001 and P=0.042, respectively). 
Conclusion: Abdominal obesity correlated with the duration of 
illness in patients with ACOHGHD. Waist circumference should be 
measured in the clinic to prevent MetS, particularly in patients with a 
long history of ACOHGHD, regardless of age or sex.
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Introduction
Adults with hypopituitarism have shorter life expectancy 
com  pared with the general population. Growth hormone 
deficiency (GHD) may contribute to the 1.5­ to fourfold increase 
in cardiovascular mortality and 2.5­ to threefold increase in 
cerebrovascular mortality observed in these patients
1­3). Growth 
hormone (GH) replacement can improve body composition and 
cardio­ and cerebrovascular risk factors associated with GHD
3, 4). 
In children and adolescents with GHD, the primary role of GH 
is to promote linear growth. In adults, after achieving their final 
adult height, GH replacement in adults with persistent GHD 
prevents metabolic imbalances such as those associated with obesity, 
osteoporosis, and fatty liver
5, 6). The components of the metabolic 
syndrome (MetS) are central obesity, high blood pressure (BP), high 
serum triglyceride (TG) level, low serum high density lipoprotein 
cholesterol (HDLC), and impaired fasting glucose tolerance
7, 8). GH 
replacement in patients with GHD may increase BP and insulin 
and glucose levels, referred to as the insulin­antagonistic effect
9), or 
may decrease central obesity. Johannsson and Bengtsson
10) noted 
that the adult GHD phenotype shares features such as abdominal 
obesity, dyslipidemia, and insulin resistance with the MetS, which 
represents a cluster of risk factors for cardiovascular disease and type 
2 diabetes
7, 11). A recent report showed that the prevalence of the 
MetS in adult patients with GHD is unaffected by GH replacement, 
but that baseline MetS status and obesity are strong predictors of 
the development of the MetS after GH treatment
12). However, 
little is known about metabolic derangements in adult patients 
with childhood­onset hypopituitary growth hormone deficiency 
(ACOHGHD) being treated with pituitary hormone replacement 
including GH.
The aims of this study were to evaluate the prevalence of the 
MetS and to analyze the risk factors for metabolic abnormalities 
in patients with ACOHGHD being treated with hormone­
replacement therapy (HRT), and to compare relevant variables 
between patients with ACOHGHD being treated with HRT and 
healthy young adults.
Materials and methods
1. Patients
The total subject pool was 109 patients (63 men, 46 women) 
with ACOHGHD being treated with HRT, who visited Seoul 
National University Children’s Hospital between September 2009 
and February 2010. Fifty­six of these patients completed the test 
for MetS during this time, and 30 patients (15 men, 15 women) 
who met the following criteria were enrolled. The inclusion criteria 
were that: 1) the patient had achieved a final height confirmed by 
epiphyseal fusion on wrist x­ray, 2) the patient was 18 to 29 years 
of age, 3) the patient was deficient in pituitary hormone and was 
taking replacement therapy, and 4) ACOHGHD was confirmed 
by a GH provocation test and the patient was being treated with an 
adult dose of GH. The exclusion criteria were that: 1) the patient had 
not been treated with GH from the diagnosis of pituitary GHD, 
and 2) the patients had chromosomal anomalies or inborn error 
of metabolism. We used and based on the control data, 639 adults 
aged 20 to 29 years (264 males, 375 females) from the 2005 Korean 
National Health and Nutrition Examination Survey (KNHANES).
2. Methods
The patients’ medical records were examined retrospectively, and 
the following variables were recorded: age, sex, underlying diseases, 
treatment methods for underlying diseases, deficient pituitary 
functions and hormones, and the use of HRT. We measured 
height, weight, waist circumference, hip circumference, waist­to­
hip ratio (WHR), BP, and fasting laboratory values such as the 
serum concentrations of total cholesterol (TC), TG, HDLC, low­
density lipoprotein cholesterol (LDLC), fasting blood glucose 
(FBG), insulin, C­reactive protein (CRP), uric acid, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and 
total bilirubin. Body mass index (BMI) was calculated as the weight 
(kg) divided by the height (m) squared and is expressed as kg/m
2. 
Compliance with HRT was evaluated by measuring the serum 
level of insulin­like growth factor­1 (IGF­1), free thyroxine, follicle­
stimulating hormone, luteinizing hormone, and testosterone or 
estradiol. The various components of the MetS were assessed in 
both the ACOHGHD patients treated with HRT and in the 2005 
KNHANES participants. According to the criteria formulated 
by the National Cholesterol Education Program – the Adult 
Treatment Panel III (NCEP­ATP III) – the MetS was diagnosed 
if three or more of the following symptoms were present: 1) central 
obesity according to the Asian definition (waist circumference 
≥90 cm in men or ≥80 cm in women), 2) elevated TG level (≥150 
mg/dL), 3) low HDLC level (<40 mg/dL in men or <50 mg/dL in 
women), 4) elevated BP (systolic BP ≥130 mmHg and/or diastolic 
BP ≥85 mmHg), and 5) increased FBG level (≥100 mg/dL using 
the 2006 cutoff of the International Diabetes Federation (IDF)
7, 8). 
We defined the cutoff points between thin (BMI <23), 
overweight (23 ≤BMI<25), and obesity (BMI ≥25) using the 
proposed Asian Pacific Island population cutoff points according 
to the World Health Organization and the International Obesity 
Task Force
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0.1 cm at the narrowest point between the lowest rib and the 
uppermost lateral border of the right iliac crest. BP was measured 
after the subject had rested for 5 minutes in a sitting position and 
was recorded as the mean of two measurements. The homeostasis 
model assessment­insulin resistance (HOMA­IR) index and the 
quantitative insulin­sensitivity check index (QUICKI) for insulin 
resistance and sensitivity were calculated using the following 
equations:
HOMA­IR=[fasting glucose (mmol/L)×fasting insulin (mg/dL)]/22.5
QUICKI=1/[log(I0)+log(G0)], where I is fasting insulin concentration 
(μ U/mL) and G0 is FBG concentration (mg/dL).
3. Statistics
The patients’ age, sex, and duration of illness are presented as 
mean and standard deviation. The data for underlying diseases 
and multiple pituitary hormone deficiencies were analyzed using 
frequency analysis. The Kruskal­Wallis test was used to analyze 
the changes in the components and related laboratory results of the 
MetS in subjects categorized by BMI. Components of the MetS 
were compared between patients and KNHANES participants 
using an independent t test or the Mann­Whitney U test. Spear­
man’s correlational analysis and univariate and multivariate linear 
regression analyses were used to identify the causative factors for 
central obesity. The relative risk and 95% confidence interval 
were analyzed using Fisher’s exact test to compare the prevalence 
of metabolic abnormalities between patients and KNHANES 
participants. The data were analyzed using SPSS version 12.0 for 
Windows (SPSS Inc., Chicago, IL, USA), and a P value <0.05 was 
considered significant.
Results
1. Clinical information for patients with ACOHGHD 
The mean age was 23.1 years and this did not differ between men 
and women. The mean age of onset of the underlying disease was 
9.6 years. The median of BMI was 24.0 kg/m
2 (range, 18.9­39.8). 
The mean duration of hypopituitary GHD was 15.7 years, and the 
mean duration of GH treatment was 10.1 years. The underlying 
diseases of GHD included a germ cell tumor in 10 patients (33.3%), 
craniopharyngioma in seven patients (23.3%), medulloblastoma 
in four patients (13.3%), and idiopathic disease in three patients 
(10.0%). Before and after the treatment for underlying diseases, 13 
patients (43.4%) developed all form of pituitary dysfunction, such 
as GHD, hypothyroidism, hypogonadism, hypocortisolism, and 
diabetes insipidus; seven patients (23.3%) showed GHD plus one 
other pituitary hormone deficiency; and three patients (10.0%) had 
isolated GHD (Table 1).
2. Correlation between parameters of the MetS and BMI 
Three groups (thin, overweight, and obese) were classified 
according to BMI. Of the various metabolic parameters tested, 
including waist circumference, hip circumference, WHR, BP, and 
levels of TC, TG, HDLC, FBG, fasting insulin, CRP, uric acid, 
AST, ALT, TB, and IGF­1, only WHR correlated significantly 
with BMI (P=0.002).  The level of uric acid (P=0.078) and the ALT 
(P=0.052) were not significant, but they were associated with BMI. 
The number of abnormal components of the MetS according to the 
NCEP­ATP III criteria showed a significant increase according to 
Table 1. The Clinical Characteristics of the Patients (N=30)
Clinical Manifestations N (%)
Age (yr)
Sex (M/F)
BMI (kg/m
2), median (range)
Onset age of Underlying Disease (yr)
Duration of GHD (yr)
Duration of GH treatment (yr)
Underlying Causes of GHD
  Germ Cell Tumor 
  Craniopharyngioma
  Medulloblastoma
  Idiopathic
  Others
†
Multiple Pituitary Hormone Deficiency
  GHD
  GHD+1 Hormone
  GHD+2 Hormones
  GHD+3 Hormones
  GHD+4 Hormones
23.1 (3.1)*
 15/15
24.0 (18.9-39.8)
9.6 (4.5)*
15.7 (5.4)*
10.1 (4.7)*
10 (33.3)
 7 (23.3)
 4 (13.3)
 3 (10.0)
 6 (20.0)
3 (10.0)
7 (23.3)
4 (13.3)
3 (10.0)
13 (43.3)
*Mean (SD)
†Others include Langerhan’s cell histiocytosis, optic glioma, pilocytic 
astrocytoma, primitive neuroectodermal tumor, agenesis of septum 
pallucidum, mycobacterial meningitis.
Abbreviations : GHD, growth hormone deficiency
Table 2. Prevalence of the Metabolic Syndrome according to Body 
Mass Index
Parameters
Thin
(N=10)
Overweight
(N=7)
Obese
(N=13)
P-
value*
WHR
Uric Acid
ALT
No. of Metabolic Abnormalities
0 factor (%)
1 facotr (%)
2 factors (%)
3 factors (%)
0.81 (0.05)
†
5.00 (1.18)
†
11 (2-33)
‡
6 (60.0)
2 (20.0)
2 (20.0)
0 (  0.0)
0.90 (0.07)
†
5.57 (1.28)
†
17 (9-90)
‡
2 (28.6)
3 (42.9)
2 (28.6)
0 (  0.0)
0.92 (0.07)
†
6.80 (2.47)
†
20 (9-36)
‡
1 (  7.7)
5 (38.5)
4 (30.8)
3 (23.1)
0.002
0.078
0.052
0.030
*P-valuse was calculated by Kruskal-Wallis Test
†This result represents mean±SD
‡This result means median (range)
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elevated BMI (P=0.030) (Table 2).
3. The number of abnormal components of the MetS 
according to the NCEP-ATP III criteria 
In men, waist circumference was significantly higher in patients 
with ACOHGHD than in KNHANES participants, and 
diastolic BP and TG level were significantly lower in patients. In 
women, waist circumference, systolic BP, and serum TG level were 
significantly higher in ACOHGHD patients than in KNHANES 
participants. HDLC and FBG levels did not differ between 
ACOHGHD patients and KNHANES participants. Diastolic BP 
in men (P<0.001) and TG level in women (P<0.001) differed the 
most between ACOHGHD patients and KNHANES participants 
(Table 3).
4. Risk factors for central obesity in ACOHGHD patients 
Correlational analysis was used to determine whether waist 
circumference was related to components of the MetS, related 
laboratory blood tests for the MetS, age, and the duration of 
illness. Waist circumference correlated significantly with the levels 
of uric acid and ALT, the number of MetS components, and the 
duration of illness. However, after controlling for the mutual 
relationships between variables including age, only the duration of 
GHD correlated significantly with waist circumference (r
2=0.546, 
P=0.003) (Fig. 1).
5. Prevalence of individual metabolic risk factors and the 
MetS (NCEP-ATP III criteria and the 2006 IDF cutoff) in 
ACOHGHD patients and 2005 KNHANES participants 
The prevalence of central obesity was higher in ACOHGHD 
patients than in KNHANES participants (P<0.001). Other 
components did not differ significantly between groups, but 
hypertension was associated with ACOHGHD (P=0.054). The 
prevalence of the MetS was significantly higher in ACOHGHD 
patients than in KNHANES participants (10% vs 2.3%, res­
pectively, P=0.042) (Table 4).
Discussion
This study showed that the prevalence of the MetS was higher 
Table 3. Comparison of Metabolic Components Between ACOHGHD Patients and 2005 KNHANES Participants
Male Female
Patients KNHANES P-value* Patients KNHANES P-value*
WC (cm)
SBP (mmHg)
DBP (mmHg)
TG (mg/dL)
HDLC (mg/dL)
FBG (mg/dL)
89.1 (  9.4)
119.7 (11.8)
66.1 (  6.7)
110.9 (68.0)
50.9 (16.6)
80.9 (13.2)
79.7 (0.6)
114.9 (0.7)
76.2 (0.7)
113.9 (5.2)
44.5 (0.7)
86.3 (0.6)
0.018
0.133
<0.001
0.031
†
0.251
†
0.139
82.0 (14.4)
114.1 (10.5)
65.7 (10.4)
132.8 (64.6)
47.5 (11.7)
81.9 (  9.2)
72.0 (0.6)
103.9 (0.6)
69.1 (0.6)
83.8 (2.6)
49.4 (0.6)
84.4 (0.5)
0.017
0.002
0.231
<0.001
†
0.547
0.315
*This results were analyzed using independent t test
†This results were analyzed using Shapiro-Wilk test and Mann-Whitney U test
Abbreviations : ACOHGHD, young adults with childhood-onset hypopituitary growth hormone deficiency; KNHANES, Korean National Health and Nutrition 
Examination Survey; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDLC, high density lipoprotein 
cholesterol; FBG, fasting blood glucose 
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Fig. 1. Correlation between waist circumference and duration of 
hypopituitarism. Multivariate linear analysis showed that the severity of 
central obesity correlated positively with the duration of hypopituitary 
growth hormone deficiency.
Table 4. Prevalence of Metabolic Abnormalities (NCEP-ATP III Criteria) 
in ACOHGHD Patients and 2005 KNHANES Participants
Patients
N=30 (%)
KNHANES
N=639 (%)
Relative Risk
(95% CI)
P-
value*
Abdominal Obesity*
Hypertension
Hypertriglyceridemia
Low HDL-C
Hyperglycemia
Metabolic Syndrome
15 (50.0)
6 (20.0)
6 (20.0)
12 (40.0)
2 (  6.7)
3 (10.0)
22 (  3.4)
57 (  8.9)
72 (11.3)
230 (36.0)
12 (  1.9)
15 (  2.3)
14.52 (8.42-25.04)
2.24 (1.05-4.78)
1.78 (0.84-3.75)
1.11 (0.71-1.74)
3.55 (0.83-15.10)
4.26 (1.30-13.92)
<0.001
0.054
0.147
0.699
0.127
0.042
*This results were analyzed using Fisher’s exact test
Abbreviations : ACOHGHD, young adults with childhood-onset hypopituitary 
growth hormone deficiency; KNHANES, Korean National Health and 
Nutrition Examination Survey; NCEP-ATP III, National Education Cholesterol 
Program-Adult Treatment Panel III, HDL, high density lipoprotein; CI, 
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in ACOHGHD patients treated with an appropriate dose of 
HRT including GH than in the age­matched general population 
(10% vs 2.3%, respectively, P=0.042). The prevalence of central 
obesity was significantly higher in the patients than in the general 
population (P<0.001). Multivariate linear analysis showed a 
significant correlation between central obesity and the duration of 
hypopituitarism (r
2=0.546, P=0.003).
Obesity is a cardinal feature of the MetS. Insulin resistance can be 
caused by central obesity and can lead to metabolic complications
7). 
Previous reports show that in the general population, the prevalence 
of the MetS increases with age in parallel with age­related increases 
in the prevalence of obesity and, in particular, central obesity
15­17). 
The HOMA­IR and QUICKI are methods to quantify insulin 
resistance and sensitivity, respectively
18). In this study, central 
obesity was the most prominent feature that differed between the 
ACOHGHD patients treated with HRT and the KNHANES 
participants. However, HOMA­IR, QUICKI, and HDLC and 
FBG levels did not differ significantly between groups. In the 
ACOHGHD patients, the severity of central obesity correlated 
positively with the duration of hypopituitary GHD but not with 
age. These results suggest the existence of an additional, unidentified 
cause of the MetS in ACOHGHD patients. Attanasio et al
12) 
suggested that patients exhibit metabolic abnormalities caused by 
GHD and possibly inadequate replacement therapy in addition to 
preexisting, GHD­independent conditions, notably obesity and its 
consequences. They suggested that it is difficult to establish to what 
extent the MetS in an individual patient is caused by GHD alone or 
by preexisting obesity or both. Two recent studies reported no effect 
of GH replacement on the prevalence of MetS defined by NCEP­
ATP III criteria in GHD patients
19, 20). In longitudinal population­
based cohort studies, the persistence of the MetS was found to 
be variable and to be influenced by factors such as aging, new 
treatment interventions, and intraindividual variability of laboratory 
measurements
21). However, a significant reduction in central obesity, 
as shown by reduced waist circumference, may reflect the effect of 
GH treatment
22). In patients with hypopituitarism, HRT cannot 
provide perfect physiological hormone regulation or balance. The 
difference (mean interval of 5.6 years in our study) between the 
duration of illness and the duration of GH treatment may influence 
adverse metabolic consequences such as metabolic syndrome. 
The MetS may be influenced by the underlying disease itself, 
drugs such as anticancer agents, antibiotics, immune modulators, 
radiation therapy, related hypothalamic conditions, and multiple 
pituitary hormone deficiencies. We hypothesized that the central 
obesity in ACOHGHD patients with HRT developed because of 
accumulation of the effects mentioned above and that there would 
be minimal differences in relation to illness duration. However, 
in this study, waist circumference or the MetS did not correlate 
significantly with the underlying diseases, treatment, duration of 
GH use, or the extent of pituitary dysfunction, although we did not 
study preexisting obesity.
In the general population, the age­adjusted prevalence of 
the MetS differs somewhat between women and men, but the 
direction of that difference is inconsistent between cohorts
7, 12, 23, 
24). In contrast to the general population, the women in the present 
GHD cohort had a higher relative risk for the MetS. Such higher 
risk in women has been reported in adult hypopituitary GHD 
patients. A recent study of 750 adult Swedish GHD patients found 
an increased prevalence of type 2 diabetes mellitus in women 
compared with men, suggesting that aspects related specifically 
to GHD or hypopituitarism contribute to this difference
9, 12, 25). 
The 2005 KNHANES data showed that the prevalence of the 
MetS in people in their 20s was 4.7% of men and 1.2% of women 
(The results did not described in Table 3). In our study, systolic 
BP, diastolic BP, TG level, and the prevalence of the MetS differed 
between men and women (Table 3). The prevalence of the MetS 
in the GH­treated ACOHGHD patients aged 18­29 years was 
6.7% in men and 13.3% in women (The results did not described 
in Table 3). The higher prevalence of the MetS in women with 
ACOHGHD might be associated with higher TG levels in these 
patients than in the KNHANES participants (P<0.001) or in men 
with ACOHGHD. However, it is unclear whether the higher TG 
level was an effect of GH treatment or why TG level was higher in 
women than in men in our study.
A few reports found that the adult­onset form GHD is more likely 
to be associated with the MetS than is childhood­onset GHD
26­
28). These reports suggested that one major reason for this may be 
the difference in the age ranges of patients in the two onset groups 
because of the developmental nature of their condition. Childhood­
onset GHD patients are exposed to the consequences of GHD or 
hypopituitarism from childhood and may accumulate metabolic 
risks. However, the childhood­onset GHD patients’ thresholds for 
abnormaities of the individual MetS components may not be similar 
to normal adult populations. In this respect, these reports noted 
that there are limited and inconsistent data on the morbidity and 
mortality of adult patients with childhood­onset GHD.
We found a significant relationship between waist circumference 
and the duration of illness, suggesting that they may be important 
factors when assessing the risk of the MetS in ACOHGHD pa­
tients with HRT. The current primary goal in the treatment of 
hypopituitary GHD patients with HRT is to maintain the normal 
range of pituitary hormone levels. Our data suggest that the Korean J Pediatr 2010;53(10):892-897 • DOI: 10.3345/kjp.2010.53.10.892    897
patient’s waist circumference, an indicator of central obesity, should 
also be checked as part of the strategy in the prevention of and early 
intervention for the MetS and related complications, especially in 
patients with a long history of GHD or hypopituitary illness.
Our study has some limitations. It used a retrospective cross­
sectional design with a small number of young patients. We did not 
correct for other possible contributors to the MetS, such as nutrition, 
physical inactivity, alcohol intake, smoking, socioeconomic status, 
family history. Long­term follow­up studies of larger groups are 
needed to understand the changes in metabolic derangement after 
childhood in these patients. 
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